For patients with chronic obstructive pulmonary disease (COPD), the Global Initiative on Obstructive Lung Disease recommends long-term term pharmacologic and nonpharmacologic therapies based on each ...
A GSK drug that targets a pathway behind the lung inflammation in chronic obstructive pulmonary disease, or COPD, has won a long-awaited FDA approval, positioning the biologic medicine to reach ...
Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD) last fall. Most COPD treatments ...
May 23, 2025 -- The FDA has approved the asthma drug Nucala for adults with chronic obstructive pulmonary disease (COPD). It is the second biologic therapy approved for the condition, following the ...
Recent medical research reveals promising developments in the treatment of patients suffering from both diabetes and chronic obstructive pulmonary disease. The study, involving nearly 394,000 adults, ...
Biologic medicines are making inroads into chronic obstructive pulmonary disease (COPD), with two blockbuster antibodies expanding their FDA-approved uses to this lung disorder in the past year. A ...
Verona Pharma recently got approval for ensifentrine in COPD. Ensifentrine has a differentiated MoA and superior safety profile. Despite a diverse market, Verona will find its own place here. Verona ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback